Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Case Report

Volume 7, Number 3, September 2018, pages 120-123

Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report

Figures

Figure 1.
Figure 1. The bone marrow aspirate smear shows myeloid hyperplasia and immature monocytoid cells. No basophilia or pseudo-Gaucher cells are observed.
Figure 2.
Figure 2. Bone marrow monocytic differentiation using eight color EuroFlow Consortium tube (CD35, CD64, CD34, CD117, CD300e, CD14, HLADR and CD45) and the Infinicyt™ analysis software. The different colors reflect the distinct differentiation stages from the more immature monocytic cells (cyan events) to mature cells (dark blue events). The arrows show the profile of monocyte maturation. APS: automated population separator.
Figure 3.
Figure 3. Absolute leukocyte (WBC) and monocyte levels during 3 years of follow-up. The A line marks the upper normal limit for WBC (× 109/L) and the B line marks the upper normal limit for monocytes (× 109/L). The vertical red hatched line indicates the starting point of dasatinib treatment.
Figure 4.
Figure 4. P190 ABL-BCR/ABL% trend during follow-up. To the left side of the black vertical line the values of p190 ABL-BCR/ABL% during imatinib treatment are shown, while to the right the p190 ABL-BCR/ABL% levels during dasatinib are indicated. In all measurements with p190 ABL-BCR/ABL% lower than 0.1, the copy number of ABL was always > 100,000. The horizontal red line indicates the established level for DMR, according to reference [8].